$10M Private Placement Extends Cash Runway to 2028, Manufacturing Strategy Updated
GRCE sits 18% above its 52-week low of $1.79 on light trading volume (0.3× avg).
Summary
Grace Therapeutics raised $10 million in a private placement at $2.10 per share, pricing at-the-market and extending its cash runway to the end of 2028. This follows the FDA's rejection of GTx-104 in June and the subsequent Type A meeting that clarified a resubmission path. The company also disclosed a dual-source manufacturing strategy to mitigate risks from its current contractor's compliance issues, with a technology transfer to a U.S.-based facility already underway. NDA resubmission timing now hinges on manufacturing readiness, with two possible pathways: the U.S. facility requiring 12 months of stability data, or the current contractor if it resolves FDA issues sooner. The financing removes near-term liquidity concerns and provides a clearer timeline for the lead asset's regulatory path.
At the time of this announcement, GRCE was trading at $2.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.5M. The 52-week trading range was $1.79 to $5.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.